肝素
蛋白质工程
异源的
重组DNA
计算生物学
催化效率
糖胺聚糖
合成生物学
翻译(生物学)
化学
生物化学
蛋白酶
异源表达
定向进化
生物
蛋白质生物合成
蛋白质表达
计算机科学
蛋白质折叠
可扩展性
蛋白质稳定性
生产过剩
靶蛋白
酶
生物反应器
生产(经济)
基因组工程
生化工程
生物技术
代谢工程
药物发现
作者
Yu-Han Zhao,Yi Li,XIN-YU LI,Jian-Qun Deng,Jiu-Ying Sun,Xiao-Lin Meng,C L Li,Rong Cai,Shuang Zheng,Juzheng Sheng
标识
DOI:10.1021/acssynbio.6c00195
摘要
Heparin has been the most important drug for treating thrombotic disorders for more than 60 years. However, the traditional production of heparin involves the slaughter of animals. Therefore, there is a demand for the animal-free production of heparin, such as enzymatic synthesis based on the heparin biosynthetic pathway. To achieve this, robust 6- O -sulfotransferases (6OSTs) are required to produce the 6- O -sulfation pattern in heparin, which is crucial for the biological activity. However, most native 6OSTs are derived from animal tissues and exhibit poor recombinant expression, low catalytic efficiency, and insufficient stability in E. coli . To overcome these limitations, we systematically established a two-tier engineering framework that integrated structure-guided protein repair and optimization of translation. Cross-species screening identified Oryzias melastigma 6OST-1 as an engineering-competent template. First, we constructed the variant 6OST-M10 through protein repair one-stop service-guided structural restoration combined with targeted reverse mutations. To address the long-standing challenge of low heterologous expression, we generated a synonymous rare-codon (SRC)-guided ultrahigh-throughput screening platform based on split-GFP complementation. This platform systematically tunes the translation kinetics for sulfotransferases. Ultimately, the 6OST-M10(SRC) variant was generated, which displayed an 8.375-fold increase in soluble expression and a 27-fold improvement in catalytic activity that reached 4400 IU/L under high-density fermentation. This dual-layer strategy couples structural stabilization with translational optimization to resolve the trade-offs among activity, stability, and recombinant expression that have previously limited bacterial production of animal-derived sulfotransferases and heparin synthesis in E. coli This framework provides a universal, scalable paradigm for protein engineering and enables the synthesis of bioengineered heparin and other glycosaminoglycan products without the involvement of animals.
科研通智能强力驱动
Strongly Powered by AbleSci AI